ACP-196
Sponsors
Acerta Pharma BV
Conditions
Glioblastoma MultiformeHealthy ParticipantsHealthy VolunteersHepatic InsufficiencyMetastatic Pancreatic Cancer
Phase 1
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Active, not recruitingNCT02586857
Start: 2016-01-25End: 2026-04-01Updated: 2026-03-25
A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants
CompletedNCT04867980
Start: 2016-04-01End: 2016-05-09Updated: 2021-04-30
A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196
CompletedNCT04867941
Start: 2014-10-21End: 2015-02-02Updated: 2021-04-30
A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole
CompletedNCT04876807
Start: 2016-01-28End: 2016-03-15Updated: 2021-05-07
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants
CompletedNCT04901923
Start: 2014-03-15End: 2014-05-22Updated: 2021-05-26
A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196
CompletedNCT04914936
Start: 2014-09-21End: 2014-10-16Updated: 2021-06-07
Phase 2
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
CompletedNCT02362048
Start: 2015-05-31End: 2017-03-31Updated: 2019-10-01
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
TerminatedNCT02570711
Start: 2015-10-13End: 2016-04-30Updated: 2019-08-28